Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas
about
The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in TherapyTransforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumabEpidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptorsNrdp1/FLRF is a ubiquitin ligase promoting ubiquitination and degradation of the epidermal growth factor receptor family member, ErbB3A collection of breast cancer cell lines for the study of functionally distinct cancer subtypesA hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factorPositive and negative regulation of endogenous genes by designed transcription factorsInduction of the Tat-binding protein 1 gene accompanies the disabling of oncogenic erbB receptor tyrosine kinasesThe ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferationNeuregulin-induced ErbB3 downregulation is mediated by a protein stability cascade involving the E3 ubiquitin ligase Nrdp1ErbB receptors: from oncogenes to targeted cancer therapiesEssential function for ErbB3 in breast cancer proliferationTrastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancerFunctional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.Analysis of different HER-2 mutations in breast cancer progression and drug resistanceA paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapyTargeting of erbB3 receptor to overcome resistance in cancer treatmentThe Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor FamilyPI3K mutations in breast cancer: prognostic and therapeutic implicationsP21-activated kinase-1 phosphorylates and transactivates estrogen receptor-alpha and promotes hyperplasia in mammary epitheliumDiversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactionsCorrelation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancerThe ErbB signaling network: receptor heterodimerization in development and cancerA corrole nanobiologic elicits tissue-activated MRI contrast enhancement and tumor-targeted toxicityHER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy.Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cellsHER2 somatic mutations are associated with poor survival in HER2-negative breast cancersHER2-positive breast cancer cells expressing elevated FAM83A are sensitive to FAM83A loss.Co-expression of HER2 and HER3 receptor tyrosine kinases enhances invasion of breast cells via stimulation of interleukin-8 autocrine secretion.Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells.ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1)In Vitro and In Vivo Anti-tumoral Effects of the Flavonoid Apigenin in Malignant Mesothelioma.c-erbB3 protein expression in ovarian cancer.Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer.Heregulin-stimulated acetylcholine receptor gene expression in muscle: requirement for MAP kinase and evidence for a parallel inhibitory pathway independent of electrical activity.ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling.Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers.Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancerThe C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing.Fatty acid-binding protein 5 and PPARbeta/delta are critical mediators of epidermal growth factor receptor-induced carcinoma cell growth
P2860
Q21284978-FDA59F4C-AE09-47BA-96A7-7C761AA2EACDQ24313194-ABA1F2E9-FBD8-45FB-96E5-657F3960B0EFQ24532786-BDA398ED-9C7F-4334-ADA2-95B8F8FE873FQ24538330-6242FE64-1A4F-41E6-ABE6-BFD2CC389DBAQ24647928-1E0C994C-944D-400B-8B12-D9AF29AC19D0Q24648517-DDCB056E-D8C6-442C-9069-1E249BBF1480Q24649843-7CFD1A48-20C9-4763-9FF1-0492887FD8DAQ24651825-4F33396C-B3D0-4413-92E6-5B747EB4D265Q24678674-ACABCDC7-35EC-4321-AF07-E20C52B0FB9AQ24681497-92A059A7-2F76-4EFE-9746-D15AE770E280Q24683709-E27AB349-8B65-4FA8-956C-1C7D2A01D684Q24795054-31FC5F18-EA79-41B5-8F49-5202A7E81BCFQ24795614-DDFD6105-F563-4190-80D5-7DD351C73C82Q24813543-C2190873-CB1A-4D08-A968-483BE2A9CE46Q26797471-ED1CCCF2-CE87-4EF6-B7F9-DD8BD6CE524BQ26824462-AAEBA2B5-148A-461C-95BB-7B80FAFEF42AQ26864668-F51F7AE9-0E69-456B-A1A7-E012624CD539Q28073335-69934964-6003-417F-9DC8-646C009952A1Q28081992-4D2B999A-D1C8-4304-BDD0-E1F282D0D9C4Q28206589-03C3F755-FEAD-4CD8-9699-2EE74D1B8627Q28609149-5A2832B9-E4A4-4A11-99E2-4FE208380B46Q28728701-33679488-24D0-4072-91E7-91406441A2F7Q29617919-CC121468-D1C7-4F55-BA74-D31BA9AD87DEQ30991229-B2E03484-175C-4420-9016-5F0CAC07EFC8Q33517907-74FB0887-F41E-42EC-833E-5539F48E6695Q33564297-4B5C164C-59A0-4450-8934-DC5CCA203EFAQ33607579-50D110D3-F48A-48C8-A145-76536B1FC3CEQ33626569-6FA3678A-59AD-454D-B30D-CBAAF7E46136Q33739262-90FC2D83-7765-4BF6-9E1B-AB1D7473793BQ33743601-B1977217-F496-43AB-87D5-B27109AF83E0Q33772914-EE64781F-DD16-458D-B111-7C7413AA8DD9Q33810593-21CBDD12-DFAE-4141-A14B-D104DB90D39BQ33841195-02B126D3-3260-4B5C-BA26-35912D138E5DQ33842800-FFBD5B1F-7536-4206-A0E4-57CF8BE4E09FQ33886118-2EEFF3BE-AC56-42AF-B00B-2CCC2A591FF2Q33886341-6145EB40-B971-4659-81C1-E6E7806A4467Q33888963-776143C8-87C4-415C-AFF5-4AC9C9770991Q33890758-1C99B5A5-E706-4121-A4CD-26A5AD5BD128Q33891080-548B5521-4A6A-42F4-AFDF-09454B504619Q33911239-E0FDCA2B-9FA1-4CC1-819B-D22549385C54
P2860
Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas
description
1995 nî lūn-bûn
@nan
1995 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Cooperative signaling of ErbB3 ...... n and human mammary carcinomas
@ast
Cooperative signaling of ErbB3 ...... n and human mammary carcinomas
@en
Cooperative signaling of ErbB3 ...... n and human mammary carcinomas
@nl
type
label
Cooperative signaling of ErbB3 ...... n and human mammary carcinomas
@ast
Cooperative signaling of ErbB3 ...... n and human mammary carcinomas
@en
Cooperative signaling of ErbB3 ...... n and human mammary carcinomas
@nl
prefLabel
Cooperative signaling of ErbB3 ...... n and human mammary carcinomas
@ast
Cooperative signaling of ErbB3 ...... n and human mammary carcinomas
@en
Cooperative signaling of ErbB3 ...... n and human mammary carcinomas
@nl
P2093
P3181
P1433
P1476
Cooperative signaling of ErbB3 ...... n and human mammary carcinomas
@en
P2093
M Alimandi
P P Di Fiore
S A Aaronson
P304
P3181
P407
P577
1995-05-04T00:00:00Z